Development of Amicidins to serve as a countermeasure/therapeutic intervention for Sepsis, field care for MCM in burn/blast/chem, and altering the future of packaging.
2026 · 2nd Quarter (Apr 1 - June 30)
MACRO BIOLOGICS, INC.
Filed by GRASSROOTS POLITICAL CONSULTING LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Aug 3, 2026
- Income
- $30,000.00
- Expenses
- Not reported
- Registrant
- GRASSROOTS POLITICAL CONSULTING LLC
- Client
- MACRO BIOLOGICS, INC.
- Filing UUID
- ba0d62d0-9106-4a59-b1a4-68ba5a8a7cc2
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.